Shared Science,
Shared Innovation.

Empowering scientists to improve skin health and innovate for a better future.
Bringing science and creativity together

Collaboration Opportunities

NEW CALL FOR IDEAS COMING SOON

In July, AlmirallShare will open a new opportunity on dermatological research. Subscribe to our newsletter and stay tuned to make your project happen!

Translational Research in Dermatology

Translational Research aims to understand the pathophysiology of diseases and translate this knowledge into a therapeutic benefit for patients with skin conditions. We encourage you to help us to make it happen. We care.

Adding value to your assets, our aim

Finding a use for existing advanced small molecules in the therapeutic treatment of atopic dermatitis, psoriasis, actinic keratosis, acne, and related dermatological diseases.

Download information Submit your proposal

Move your ideas forward

If your idea doesn’t fit with our current initiatives, share your innovative proposals with us here.

Submit your proposal

What we offer

Your idea + AlmirallShare= Reinventing skin health

Closeness, helping on project implementation

Open communication

A collaboration journey

Ideas and information managed safely and diligently

Your projects. We make them happen

Fair partnerships

News

Almirall + HitGen = novel oral compounds for AD

Almirall and HitGen entered in a multi-target research collaboration to develop novel oral chemical entities for patients suffering from moderate to severe atopic dermatitis

You are part of our success: AlmirallShare results

More than 450 scientists subscribed and over 170 different proposals received

Digital + omics = unprecedented target-disease associations

Partnership between Almirall, S.A. and Barcelona Supercomputing Center (BSC) to identify novel targets to treat dermatological diseases

SilicoDerm: new modeling techniques for dermatological research

SilicoDerm computational methodologies will facilitate the identification of active compounds for the treatment of inflammatory skin diseases

Almirall + Evotec = first-in-class dermatological therapies

Almirall S.A. and Evotec AG have entered into a research collaboration to discover and develop first-in-class therapies for debilitating dermatology diseases

Almirall seeks novel targets for skin health

We provide research funding for work on novel targets and concepts which may form the basis for new medicines in dermatological diseases

Adding value to your assets, AlmirallShare new call

Almirall seeks new compounds to treat atopic dermatitis, psoriasis, actinic keratosis, acne, and related dermatological diseases.

More than 100 proposals received at AlmirallShare

Scientists from all over the world have been registered on AlmirallShare and submit their solutions to improve skin health.

One month left to participate in Preclinical Models call

Deadline of December, 31th, 2017. Preclinical Models call is offering financial and scientific support to develop novel pharmacologically validated in vitro and in vivo research translational preclinical models in skin diseases.

AlmirallShare launch

Almirall launches AlmirallShare, an Open Innovation platform, aimed to bring together creative minds and team up with experts around the world to find innovative solutions for skin health.

Almirall + Leo = Unique dermatology research collaboration

Almirall S.A. and LEO Pharma join forces to advance understanding of skin diseases by setting a new standard for skin sampling

NANO4DERM: Making ps_ri_sis and ac_e invisible

Nano4derm is a public-private partnership project focused on the development of innovative formulations containing nanoencapsulated active ingredients for the treatment of inflammatory skin diseases, such as Acne and Psoriasis

Almirall + Mercachem = Looking for new cytokine blockers

Almirall S.A. and Mercachem have entered into an exclusive discovery collaboration focusing on the development of oral cytokine blockers for the treatment of inflammatory skin diseases.

Almirall + Nuevolution = Fighting together inflammatory skin diseases

Almirall S.A. and Nuevolution A/S have entered into a global strategic collaboration focusing on the development and commercialization of Nuevolution's novel RORγt inverse agonist (inhibitor) program for treatment of inflammatory skin diseases and disorders as well as for treatment of psoriatic arthritis.

Show more news

Shared Science, Shared Innovation.

Empowering scientists to improve skin health and innovate for a better future. Bringing science and creativity together